Clinical Policy: Radial Head Implant
Reference Number: CP.MP.148
Date of Last Revision: 05/22

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Radial head implant, or arthroplasty, was developed for the treatment of complex radial head fractures and severe arthritic conditions causing radial head joint destruction.

Policy/Criteria
I. It is the policy of health plans affiliated with Centene Corporation® that radial head implants are medically necessary when meeting the following:
   A. Has one of the following indications:
      1. Mason type III comminuted fractures of the radial head or a fracture is deemed irreparable intraoperatively;
      2. Radiographic evidence of radial head joint destruction, too far advanced to benefit from radial head excision and synovectomy, with demonstrated resistance or failure of conservative medical treatment;
   B. Has none of the following contraindications:
      1. Untreated or unresolved elbow sepsis within the past 12 months;
      2. Previous fascial or other interpositional arthroplasty, or previous hinged arthroplasty with the use of a capitellocondylar implant;
      3. Excessive bone loss on either side of the joint or poorly functioning flexor or extensor mechanism.

II. It is the policy of health plans affiliated with Centene Corporation that radial head implants are not medically necessary for any indications other than those specified above.

Background
Radial Head Fractures
Radial head and neck fractures are common and occur in about 30% of elbow fractures. The following modified Mason classification is frequently used to describe the fractures:\1,2:
- Mason Type I – nondisplaced fractures (displacement ≤ 2 mm);
- Mason Type II – displaced fractures > 2 mm;
- Mason Type III – comminuted fractures in which bone is broken, splintered or crushed into a number of pieces. Treatment includes excision, operative fixation and replacement arthroplasty;
- Mason Type IV – radial head fracture with associated elbow fracture/dislocation.

Immediate orthopedic evaluation is necessary for any individual with an open fracture, neurovascular compromise, or fracture dislocation. Immediate reduction is critical in patients who present with a radial head or neck fracture with elbow dislocation. The longer the joint is allowed to remain dislocated, the more difficult the reduction, and the greater the risk of avascular necrosis.\2-4
Studies
The peer-reviewed evidence for optimal management of Mason type III radial head fractures is unclear since there is difficulty performing randomized controlled trials due to the small number of these types of fractures. Type III comminuted fractures often do poorly with open reduction internal fixation, especially when there are more than three fragments. Additionally, there is a risk of posterior interosseous nerve injury with this procedure. Although many of the studies related to radial head implants are small, these types of prostheses are noted as an acceptable option in cases of Type III comminuted fractures. Many of these fractures will have a ligamentous injury between the radius and ulna shaft in the forearm, which are termed Essex-Lopresti injuries. Excision of a radial head fracture that has an associated Essex Lopresti injury will cause very significant shortening and wrist morbidity.5-8

The radial head implant is also beneficial in patients with rheumatoid arthritis with radiographic evidence of joint destruction that is too far advanced to benefit from radial head excision and synovectomy. In patients with rheumatoid arthritis, arthroplasty should be considered only after conservative medical treatment has failed, including, pharmacologic therapy consisting of combinations of salicylates, nonsteroidal anti-inflammatory drugs, disease modifying antirheumatic drugs, and/or glucocorticoids for 3-6 months.9

In summary, multicenter, long-term, evidence-based, peer-reviewed studies or clinical trials would be helpful to assess the benefits and/or problems associated with radial head implants.1 Additional randomized control trials for the management of Mason type III fractures are needed to fully evaluate the benefits and long-term clinical outcomes of radial head implants.6

Coding Implications
This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2021, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

<table>
<thead>
<tr>
<th>CPT®</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>24366</td>
<td>Arthroplasty, radial head; with implant</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HCPCS</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td></td>
</tr>
</tbody>
</table>

ICD-10-CM Diagnosis Codes that Support Coverage Criteria
**CLINICAL POLICY**

**Radial Head Implant**

<table>
<thead>
<tr>
<th>ICD 10 CM Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>M06.821</td>
<td>Other specified rheumatoid arthritis, right elbow</td>
</tr>
<tr>
<td>M06.822</td>
<td>Other specified rheumatoid arthritis, left elbow</td>
</tr>
<tr>
<td>S52.121 (A-S)</td>
<td>Displaced fracture of head of right radius</td>
</tr>
<tr>
<td>S52.122(A-S)</td>
<td>Displaced fracture of head of left radius</td>
</tr>
</tbody>
</table>

**Reviews, Revisions, and Approvals**

<table>
<thead>
<tr>
<th>Event Description</th>
<th>Revision Date</th>
<th>Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy Adopted from Health Net Radial Head Implant</td>
<td>07/17</td>
<td>08/17</td>
</tr>
<tr>
<td>References reviewed and updated.</td>
<td>05/18</td>
<td>05/18</td>
</tr>
<tr>
<td>Reorganized without clinical impact: moved “history of previous elbow sepsis,” “Previous fascial or other interpositional arthroplasty…,” and “Excessive bone loss…” from the not medically necessary statement to contraindications section in I. Clarified that any of the previous arthroplasties alone are contraindications, and that extensive bone loss or poor flexion or extension mechanisms are contraindications.</td>
<td>10/18</td>
<td></td>
</tr>
<tr>
<td>Added in I.A.1 “or fracture is considered irreparable intraoperatively” and in I.B.1 changed history of sepsis to untreated or unresolved sepsis in past 12 months. Specialty review.</td>
<td>05/19</td>
<td>05/19</td>
</tr>
<tr>
<td>References reviewed and updated. Replaced “member” with “member/enrollee” in all instances.</td>
<td>05/20</td>
<td>05/20</td>
</tr>
<tr>
<td>Annual Review. Changed “Review Date” in policy header to “Date of Last Revision,” and “Date” in the revision log header to “Revision Date.” Updated description and background with no impact on criteria. References reviewed and updated. Specialist reviewed.</td>
<td>05/22</td>
<td>05/22</td>
</tr>
</tbody>
</table>

**References**

Clinical Policy
Radial Head Implant


Important Reminder
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members/enrollees. This clinical policy is not intended to recommend treatment for members/enrollees. Members/enrollees should consult with their treating physician in connection with diagnosis and treatment decisions.
Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members/enrollees and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members/enrollees and their representatives agree to be bound by such terms and conditions by providing services to members/enrollees and/or submitting claims for payment for such services.

**Note: For Medicaid members/enrollees,** when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

**Note: For Medicare members/enrollees,** to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs, LCDs, and Medicare Coverage Articles should be reviewed prior to applying the criteria set forth in this clinical policy. Refer to the CMS website at [http://www.cms.gov](http://www.cms.gov) for additional information.

©2017 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.